A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides

J Neurosci. 2009 Jan 28;29(4):918-29. doi: 10.1523/JNEUROSCI.3952-08.2009.

Abstract

Nicotinic acetylcholine receptors (nAChRs) containing alpha7 subunits are thought to assemble as homomers. alpha7-nAChR function has been implicated in learning and memory, and alterations of alpha7-nAChR have been found in patients with Alzheimer's disease (AD). Here we report findings consistent with a novel, naturally occurring nAChR subtype in rodent, basal forebrain cholinergic neurons. In these cells, alpha7 subunits are coexpressed, colocalize, and coassemble with beta2 subunit(s). Compared with homomeric alpha7-nAChRs from ventral tegmental area neurons, functional, presumably heteromeric alpha7beta2-nAChRs on cholinergic neurons freshly dissociated from medial septum/diagonal band (MS/DB) exhibit relatively slow kinetics of whole-cell current responses to nicotinic agonists and are more sensitive to the beta2 subunit-containing nAChR-selective antagonist, dihydro-beta-erythroidine (DHbetaE). Interestingly, presumed, heteromeric alpha7beta2-nAChRs are highly sensitive to functional inhibition by pathologically relevant concentrations of oligomeric, but not monomeric or fibrillar, forms of amyloid beta(1-42) (Abeta(1-42)). Slow whole-cell current kinetics, sensitivity to DHbetaE, and specific antagonism by oligomeric Abeta(1-42) also are characteristics of heteromeric alpha7beta2-nAChRs, but not of homomeric alpha7-nAChRs, heterologously expressed in Xenopus oocytes. Moreover, choline-induced currents have faster kinetics and less sensitivity to Abeta when elicited from MS/DB neurons derived from nAChR beta2 subunit knock-out mice rather than from wild-type mice. The presence of novel, functional, heteromeric alpha7beta2-nAChRs on basal forebrain cholinergic neurons and their high sensitivity to blockade by low concentrations of oligomeric Abeta(1-42) suggests possible mechanisms for deficits in cholinergic signaling that could occur early in the etiopathogenesis of AD and might be targeted by disease therapies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / metabolism*
  • Acetylcholine / pharmacology
  • Amyloid beta-Peptides / pharmacology*
  • Animals
  • Animals, Newborn
  • Cells, Cultured
  • Choline O-Acetyltransferase / metabolism
  • Cholinergic Agents / pharmacology
  • Dose-Response Relationship, Drug
  • Immunoprecipitation / methods
  • Membrane Potentials / drug effects
  • Membrane Potentials / genetics
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neurons / drug effects*
  • Neurons / metabolism*
  • Oocytes
  • Patch-Clamp Techniques / methods
  • Peptide Fragments / pharmacology*
  • Prosencephalon / cytology
  • Protein Subunits / genetics
  • Protein Subunits / metabolism*
  • Rats
  • Rats, Wistar
  • Receptors, Nicotinic / chemistry*
  • Receptors, Nicotinic / deficiency
  • Receptors, Nicotinic / genetics
  • Receptors, Nicotinic / metabolism
  • Xenopus laevis
  • alpha7 Nicotinic Acetylcholine Receptor

Substances

  • Amyloid beta-Peptides
  • Cholinergic Agents
  • Chrna7 protein, mouse
  • Chrna7 protein, rat
  • Peptide Fragments
  • Protein Subunits
  • Receptors, Nicotinic
  • alpha7 Nicotinic Acetylcholine Receptor
  • amyloid beta-protein (1-42)
  • nicotinic receptor beta2
  • Choline O-Acetyltransferase
  • Acetylcholine